Skip to content
SEKISUI XenoTech DD Blog Logo

Meet the Scientist: Mark Horrigan

Continuing our effort to put faces to the names of some of the scientists you interact with at SEKISUI XenoTech, we interviewed one of our study directors, Mark Horrigan. Mark joined the company in 2005 as a Senior Mass Spectrometry Specialist and Qualitative Analysis group leader. Since then he has served as a Principal Scientist in the Drug Metabolism and Program Oversight Departments.

What responsibilities do you have as a Principal Scientist in Program Oversight?

As a Principal Scientist in the PO department I serve as a study director for metabolite characterizationreaction phenotyping and metabolic stability studies. My role is to ensure that the study is carried out according to the design specified in the protocol and to serve as the main point of communication with the sponsor.

What do you like about being a study director?

I enjoy being able to help our clients learn more about their drug candidates and solve problems with them. It is especially gratifying to work with repeat clients over the years, sometimes on the same drug candidate that has progressed to a different stage and we are helping them gain new insight that may help advance their drug candidate towards agency approval.

Do you have a “specialty” study or area that you have a lot of experience with? How has your experience has helped you become an expert?

My ‘specialty area’ is metabolite characterization. It makes up a large portion of my professional experience. Over my career I’ve worked on hundreds of studies with various small molecule test articles. Many of those studies presented some type of challenge or new aspect that helped to build my knowledge and expertise. I’m grateful to have had several very qualified and knowledgeable mentors that helped give me a good foundation and to work with a great team at SEKISUI XenoTech.

Why did you want to work for SEKISUI XenoTech (SXT) and what keeps you coming back to work?

I knew of SEKISUI XenoTech’s reputation as a leader in the drug metabolism field from my work at a previous CRO. I was very excited to have the opportunity to join SXT (XenoTech then) in 2005 to begin the metabolite characterization service. It has been a blessing to work here and I am grateful for the opportunity to play a role in continuing our reputation as a well-respected CRO. There is usually something new and challenging to learn as we help our clients develop new and/or more effective medicines.

Because the failure rate in the drug development industry is high, many of the test articles we work with are unlikely to progress to later stages. It has been meaningful to work with repeat customers that started out with early in vitro studies and later returned for assistance in preclinical or clinical stages. It is especially interesting to see how (or if) the in vitro and in vivo metabolite characterization data compare.

Read about some of our other scientific leaders

Learn more about:

About the Authors

Michael Millhollen received his bachelor's degree in Visual Communications from the University of Kansas and has over 20 years of experience in marketing and communications. As Global Marketing Manager, he is dedicated to the objective of sharing SEKISUI XenoTech’s scientific expertise and knowledge with scientists around the world.

Subscribe to our Newsletter

Stay up to date with our news, events and research

In vitro pipette test article treatment
005 International Messaging Created with Sketch.

Do you have a question or a request for upcoming blog content?

We love to get your feedback

A scientist utlilizing a microplate